HopeStage
Back to all studies
CompletedNCT00580125

PF-00217830 doses, placebo, or aripiprazole for acute schizophrenia

About this titleRead the official source — NCT00580125

This study evaluated the safety and effectiveness of PF-00217830 for people with schizophrenia.

Medication studyAges 18+Multiple countries
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of PF-00217830 for people with schizophrenia.

Who was this study for?

Listed age limits: from 18 years.

Listed locations
Garden Grove and 25 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2007
Recruitment status
Completed
Enrollment listed in the registry
164
Sponsor
Pfizer
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, India, Russia, ...
Age range
Over 18 Years
Official registry ID
NCT00580125
Official title
Show the full official title

A Phase 2, Multicenter, Double-Blind, Randomized, Fixed Dose, Parallel Group, 3-Week Inpatient Treatment Study To Evaluate The Dose-Response Relationship, Safety, Efficacy, And Pharmacokinetics Of PF-00217830 Compared With Placebo, Using Aripiprazole As A Positive Control, In The Treatment Of Acute Exacerbation Of Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Garden Grove, United States · Torrance, United States · Washington D.C., United States

21 more locations
  • Detroit, United States
  • Bridgeton, United States
  • Florissant, United States
  • Saint Charles, United States
  • Brooklyn, United States
  • Bangalore, India
  • Mangalore, India
  • Udupi, India
  • Pune, India
  • Gatchina District, Russia
  • Khot'kovo, Russia
  • Moscow, Russia
  • Saint Petersburg, Russia
  • Simferopol, Ukraine
  • Kiev, Ukraine
  • Dnipropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Luhansk, Ukraine
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of PF-00217830 for people with schizophrenia.

Who is behind this study?

The study sponsor is Pfizer.

Did this study involve medication?

Yes. The study involved medication, including PF-00217830 and Aripiprazole.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies